Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy

Next Previous
X
Search
Trial Profile

A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brazikumab (Primary) ; Brazikumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 20 Dec 2023 Results of brazikumab long-term safety and tolerability from the open-label period , published in the BMC Gastroenterology
    • 24 Oct 2018 Results assessing the long-term safety and tolerability of brazikumab, presented at the 26th United European Gastroenterology Week
    • 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top